share_log

6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines

6-K: Jean-Paul Kress to join Sanofi's Board of Directors and Sanofi Initiates Phase 3 Program for PCV21 and Expands Collaboration with Sk Bioscience for Next-Generation Pneumococcal Conjugate Vaccines

6-K:Jean-Paul Kress將加入賽諾菲安萬特董事會以及賽諾菲安萬特啟動PCV21第三階段研究計劃,並擴大與SK bioscience的下壹代肺炎球菌結合疫苗合作
美股SEC公告 ·  12/24 03:11
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息